摘要
背景与目的:泰素(Taxol)联合顺铂(cisplatin,DDP)经静脉给药治疗晚期非小细胞肺癌(non-smallcelllungcancer,NSCLC),疗效较以往其他方案有所提高,但仍然不够理想。本研究的目的是比较晚期NSCLC患者经供瘤支气管动脉介入灌注化疗和经静脉化疗的临床疗效。方法:57例NSCLC患者随机分为靶动脉给药组(A组)和静脉给药组(B组)。A组27例,Taxol135mg/m2,供瘤支气管动脉灌注3h,DDP80mg/m2,动脉灌注1h,d1;B组30例,Taxol135mg/m2,DDP80mg/m2,静脉点滴3h,d1。3～4周后重复,至少治疗2个周期。结果:近期疗效以CT或X光检查结果作为评价标准,CR1例,PR29例,总有效率52.63%。A组CR1例,PR17例,有效率为66.67%(18/27);B组无CR,PR12例,有效率为40.00%(12/30),两组有效率有显著性差异。A组中位疾病进展期(TTP)5.5个月,中位生存期13.5个月,0.5、1、2和3年生存率分别为85.18%、66.67%、48.15%和18.51%;B组TTP4.0个月,中位生存期10.5个月,0.5、1、2和3年生存率分别为70.00%、53.33%、30.00%和6.67%。不良反应主要为骨髓抑制、胃肠道反应和周围神经炎,经大量维生素、制酸、止呕、水化和应用升白细胞药物对症治疗后可缓解。结论:供瘤支气管动脉灌注Taxol和DDP是治疗晚期NSCLC的一种有效方法,供瘤支气管动脉给药后病灶局控率优于静脉?
Background & Objective: Although previous studies showed that intravenous infusion chemotherapy combined with Taxol and cisplatin(DDP) can improve the effects of the treatment of advanced non small cell lung cancer (NSCLC), the results remained unsatisfactory because of the lower concentration of local chemotherapeutic agent. This study was designed to administrate the chemotherapeutic agents through the local artery and to evaluate the efficacy of the intraartery (IA) and the intravenous (IV) infusion chemotherapy combined Taxol with cisplatin (DDP) in the treatment of NSCLC. Methods: Fifty seven patients with advanced NSCLC were enrolled and randomized into two groups. Group A (27 patients ) was given by IA chemotherapy consisting of Taxol 135 mg/m2 and DDP 80 mg/ m2 within 3 hours in the first day. Group B (30 patients) was given by IV chemotherapy consisting of Taxol 135 mg/m2 and DDP 80 mg/m2 within 3 hours in the first day. The patients in two groups were repeatedly treated every 3～4 weeks for at least 2 cycles. Results: The recent effect was evaluated by the CT or X ray results. Of the 57 patients, 1 case acquired complete response,29 partial response.The overall response rate was 52.63% with 66.67%(18/27) in group A and 40.00% (12/30) in group B.The median TTP was 5.5 months in group A and 4.0 months in group B.The median survival time was 13.5 months in group A and 10.5 months in group B. The 0.5,1,2,and 3 year survival rates were 85.18%,66.67%,48.15%,and 18.51% months in group A,respectively.The 0.5,1,2,and 3 year survival rates were 70.00%,53.33%,30.00%,and 6.67% months in group B,respectively.The main side effects were myelosuppression,gastrointestinal reactions and peripheral neuropathy. They could be effectively treated with large amount of vitamines,antacid,guastil,white blood cell stimulating drugs and liquid compensation. Conclusion:The artery infusion Taxol and DDP chemotherapy is one of the useful methods in the treatment of NSCLC patients.The local response rate in the patients treated by IA may be higher than those treated by IV.
出处
《癌症》
SCIE
CAS
CSCD
北大核心
2002年第12期1365-1367,共3页
Chinese Journal of Cancer
关键词
治疗
疗效
非小细胞肺癌
泰素
顺铂
动脉化疗
静脉化疗
Non small cell lung cancer
Taxol
Cisplatin
Intraartery chemotherapy
Intravenous chemotherapy
